Evofem biosciences, inc. (EVFM)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14
Cash flows from operating activities:
Net loss

-81,111

-80,033

-82,297

-86,930

-74,724

-125,712

-130,224

-185,824

-169,092

-105,305

-141,432

-69,763

-65,909

-66,667

-20,561

-35,461

-42,281

-43,157

-36,538

-23,317

-16,119

-10,819

0

0

0

Adjustments to reconcile net loss to net cash, cash equivalents and restricted cash used in operating activities:
Loss on issuance of warrants

-

-

-

-

-

-

-56,442

-56,442

-56,442

-8,522

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

3,315

7,755

7,755

7,755

4,440

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

860

0

0

0

Liabilities, Fair Value Adjustment

-

-

-

-

-

-130

-1,494

-60,705

-60,955

-61,175

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest expense on notes payable and debt

-

-

-

-

-

-

-

-

-

-

-

-

-

-

158

216

213

220

196

178

128

84

0

0

0

Stock-based compensation

10,018

8,579

8,496

10,968

19,116

17,842

16,300

11,781

1,330

861

1,107

974

935

1,431

1,506

1,789

1,993

1,578

1,298

1,070

813

612

0

0

0

Loss on sale of assets

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-6

0

0

0

-

-

-

-

Depreciation

266

263

264

263

263

262

261

262

261

244

218

169

122

92

70

70

72

58

45

31

16

17

0

0

0

Noncash lease expenses

649

642

487

319

157

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Prepaid and other assets

1,991

952

212

531

-575

11

200

375

334

-145

1,482

1,317

1,149

153

-486

-57

313

1,051

-137

653

632

783

0

0

0

Accounts payable

-4,822

-2,931

1,672

5,078

2,722

3,799

2,409

4,337

10,211

7,052

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued expenses and other liabilities

-9,232

-8,775

-8,120

-3,722

-933

-795

8,011

5,919

9,359

7,319

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Accrued compensation

1,015

746

355

521

2,586

307

284

-46

-235

775

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Operating lease liabilities

772

761

576

378

186

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred rent, net of current portion

-

-

-

-

-

242

239

226

208

30

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash used in operating activities

-62,295

-55,097

-51,898

-46,401

-46,040

-56,500

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable and accrued expenses

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-8,602

-2,220

-399

4,433

7,938

3,724

2,446

455

0

0

0

Net cash, cash equivalents and restricted cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-23,716

-22,879

-24,417

-26,941

-35,547

-40,714

-37,911

-27,484

-17,484

-11,592

-9,572

0

0

0

Cash flows from investing activities:
Maturities of short-term investments

250

250

250

250

250

250

250

250

250

250

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Maturities of short-term investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash acquired in connection with the Merger

-

-

-

-

-

1,900

1,900

1,900

1,900

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

Purchases of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

226

237

241

241

18

0

0

0

Purchases of property and equipment

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

-1,463

-8,115

-3,495

243

243

2,143

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by investing activities

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-226

-437

-441

-441

-18

0

0

0

Cash flows from financing activities:
Proceeds from issuance of common stock- exercise of warrants

0

6,273

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

29,925

9,925

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock, net of commissions- ATM transactions

1,424

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepayment resulting in debt extinguishment

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Principal payments on bank loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Loan amendment costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

-

-

-

-

-

-

-

-

Principal payments on bank loan

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

0

Proceeds from issuance of common stock - exercise of stock options

0

-

0

0

0

-

42

42

42

0

0

0

0

-

-

-

-

-

-

-

-

76

0

0

0

Payment of cash dividends for Series D redeemable convertible preferred stock

-

-

-

-

-

157

157

157

157

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of preferred stock for cash, net of offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

13,568

0

0

0

Cash paid for financing costs

0

-

0

0

0

-

-

-

-

713

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Payments of tax withholdings related to vesting of restricted stock awards

1,585

1,566

711

2,116

1,598

1,592

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

73,173

78,076

75,377

73,896

40,799

54,417

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net change in cash, cash equivalents and restricted cash

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash, cash equivalents and restricted cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

23,446

23,533

18,061

0

0

0

-

-

-

-

81,173

0

0

0

Net change in cash, cash equivalents and restricted cash

-

-

-

-

-

-

8,357

21,795

510

-9,786

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Supplemental disclosure of noncash investing and financing activities:
Right-of-use assets obtained in exchange for operating lease liabilities

266

802

802

802

802

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Financing costs included in accounts payable and accrued expenses

0

-

0

0

0

-

521

911

513

137

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Purchases of property and equipment included in accounts payable and accrued expenses

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net decrease in cash, cash equivalents and restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

-

-

-

-

-

-

-

-

Net (decrease) increase in cash and cash equivalents

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

61,215

-

0

0

0

Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

73

1,046

901

918

912

657

567

574

351

0

0

0

Net assets acquired in connection with the Merger

-

-

-

-

-

46

46

46

46

0

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

121,315

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series D Convertible Preferred Stock
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

68,622

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Series D 2X Liquidation Preference Liability
Conversion of Series D redeemable convertible preferred stock into common stock

-

-

-

-

-

80,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-